key: cord-0973840-b1nl7l22
authors: Shirakawa, Jun
title: Pancreatic β‐cell fate in subjects with COVID‐19
date: 2021-09-27
journal: J Diabetes Investig
DOI: 10.1111/jdi.13671
sha: c572a65bc2851c8a7cec7280395743373b4d01a7
doc_id: 973840
cord_uid: b1nl7l22

Two recent reports denoted the potential of SARS‐CoV‐2 to directly infect β‐cells and the possible fate of β‐cells under COVID‐19. The fight against SARS‐CoV‐2 will continue to develop more effective therapeutic strategies for diabetes. [Image: see text]

in the b-cells of subjects with COVID-19. Two recent reports in Cell Metabolism 6, 7 denoted the potential of SARS-CoV-2 to directly infect b-cells and the possible fate of b-cells under COVID-19.

Wu et al. 6 from Stanford University indicated that SARS-CoV-2 infected human b-cells through NRP1, which resulted in increased b-cell apoptosis and reduced glucose-induced insulin secretion (GSIS) (Figure 1 ). They first confirmed the messenger RNA (mRNA) expression of ACE2, TMPRSS2, NRP1, TFRC, and FURIN in human b-cells by datasets of single-cell RNA sequencing (scRNA-Seq). Notably, immunofluorescence revealed stronger NRP1 and TFRC expression in b-cells but not in a-cells. Both the SARS-CoV-2 nucleocapsid protein (NP) and spike protein (SP) were detected in bcells at 2 or 6 days post infection (dpi) when healthy human islets were infected with SARS-CoV-2 ex vivo. Pretreatment of human islets with EG00229, an NRP1 antagonist, decreased the NP-positive b-cells after infection with SARS-CoV-2 at 2 dpi, suggesting that SARS-CoV-2 requires NRP1 to enter b-cells. Pathological analysis showed the existence of SARS-CoV-2 NP and spike mRNA in insulin-positive b-cells from 4 out of 7 subjects with COVID-19. NRP1, but not ACE2, expression was elevated in b-cells of COVID-19 donors compared with non-COVID-19 donors. SARS-CoV-2 infection reduced the insulin content in islets and the insulin secretion from b-cells under high glucose conditions, and these functional impairments were recovered, at least in part, by NRP1 antagonism with EG00229. SARS-CoV-2infected human islets from healthy donors demonstrated an increase in TUNEL-positive apoptotic b-cells. Treatment with the recombinant SARS-CoV-2 SP S1 subunit also induced b-cell apoptosis. They also demonstrated that SARS-CoV-2 SP upregulated the phosphorylation of apoptotic/proapoptotic kinases, such as p21-activated kinase (PAK) and c-Jun N-terminal kinase (JNK), in human islets by phosphoproteomic analysis.

Meanwhile, Tang et al. 7 from Weill Cornell Medicine showed that SARS-CoV-2 resided in the endocrine pancreas of subjects with COVID-19 and that SARS-CoV-2 provoked b-cell transdifferentiation via the eukaryotic translation initiation factor 2 (eIF2) signaling pathway ( Figure 1 ). They first exhibited high expression of NRP1 in human b-cells, similar to the report from Tang et al. SARS-CoV-2 NP was also detected in all islet cells, and the proportion of NPpositive cells was greater in ACE2/NRP1 double-positive cells than in singlepositive or double-negative cells. SARS-CoV-2-infected human islets expressed higher chemokines, cytokines, and interferon-stimulated genes. In addition, an Ingenuity pathway analysis further implicated the eIF2 signaling pathway in the effects of SARS-CoV-2 infection on human islets. Then, they focused on the increased expression of a-cell markers and acinar cell markers in b-cells affected by reduced insulin expression in SARS-CoV-2-infected human islets. The proportion of insulin-positive b-cells that also express glucagon, an a-cell marker, or trypsin, an acinar cell marker, was significantly increased under SARS-CoV-2 infection. The ratio of trypsin immunofluorescence-positive cells was also elevated in b-cells from subjects with COVID-19. Thus, b-cells in COVID-19 subjects might undergo transdifferentiation. The trajectory analysis of the scRNA-Seq data for SARS-CoV-2infected human islets determined the process of b-cell transdifferentiation, and eIF2 signaling was identified as the most significant pathway under SARS-CoV-2induced transdifferentiation by ingenuity pathway analysis. The phosphorylation levels of both protein kinase R (PKR), an eIF2 kinase, and eIF2a were elevated in a SARS-CoV-2-infected human b-cell line. High-throughput chemical screening using human pluripotent stem cell-derived endocrine cells identified trans-integrated stress response inhibitor (trans-ISRIB) as a potential compound to decrease insulinand glucagon-positive polyhormonal cells. Remarkably, treatment with trans-ISRIB increased insulin expression and reduced glucagon, trypsin, and cell stress-associated genes in SARS-CoV-2-infected human islets or b-cells. These results suggest that trans-ISRIB reversed b-cell transdifferentiation under COVID-19 conditions.

Another recent report showed that SARS-CoV-2 directly infected pancreatic b-cells, causing morphological changes in organelles and a decrease in insulin granules, leading to decreased insulin secretion 8 . Each study has suggested the direct infection of b-cells with SARS-CoV-2; however, it is unclear whether NRP1, ACE2, or other factors are important for viral entry into b-cells. It is also unknown whether b-cells are more susceptible to infection than other islet endocrine cells, acinar cells, or endothelial cells. Since there were some cases of COVID-19 in which the SARS-CoV-2 antigen was not detected in b-cells, its associations with severity, ethnicities, and patient background in b-cell infection will also be informative in the future. It is also important to elucidate the infection route of SARS-CoV-2 to islets in the body. Is it transmitted through the bloodstream? Which organ does it migrate from? Experiments with appropriate animal models may be required to unveil the mechanism of transmission to the islets. The functions of islets and b-cells in vivo are closely controlled by interorgan networks with many other organs via humoral factors, nerves, or exosomes. Whether pancreatic b-cell damage in subjects with COVID-19 is due to direct infection of SARS-CoV-2 with bcells or due to indirect effects, such as other organ damage, cytokine storms, and inflammatory responses, requires further investigation.

Even though diabetes is clearly associated with b-cell failure, the pathogenesis of b-cell dysfunction, especially in type 2 diabetes, remains controversial. b-Cells undergo insulin hyposecretion, adaptive growth defects, apoptosis, autophagy, dedifferentiation, or transdifferentiation, which are caused by metabolic or environmental stresses, including viral infection, during the development of diabetes. While one of these processes could cause b-cell dysfunction, several of these processes probably occur simultaneously under the same stress. The reports by Wu et al. 6 Interestingly, Tang et al. 7 implicated the eIF2-mediated integrated stress response (ISR) as a pathogenic process of SARS-CoV-2-infected b-cells. The ISR is a central regulator of protein homeostasis and is activated by various pathological conditions. A variety of different stresses are sensed by eIF2 kinases, namely, heme-regulated inhibitor (HRI, EIF2AK1), protein kinase RNA-activated (PKR, EIF2AK2), PKR-like endoplasmic reticulum (ER) kinase (PERK, EIF2AK3), and general control nonderepressible 2 (GCN2, EIF2AK4), which phosphorylate eIF2a to activate the ISR. ISR-mediated translational regulation plays a pivotal role in the process of ER stress, which is a major cause of b-cell failure in the development of diabetes. Therefore, increasing attention has been given to the ISR of b-cells in research on the mechanism of b-cell dysfunction. Protective effects of compounds that modulate ISR, such as ISRIB, on pancreatic b-cell damage have been reported. The mechanisms underlying the action of these ISR modulators will be important in the development of a therapeutic strategy for protecting b-cells in subjects with COVID-19 in the future.

One of the major topics in the current epidemic situation is a SARS-CoV-2 variant with genetic changes that affect virus characteristics. Variants of concern (VOCs), such as the delta variant, or variants of interest (VOIs) may also differ in their organ-specific infectivity and pathogenic mechanisms in b-cells. The fight against SARS-CoV-2 will continue to develop more effective therapeutic strategies for diabetes. We sincerely hope for further research in protecting b-cells from COVID-19 to save people.

SARS-CoV-2 cell entry factors ACE2 and TMPRSS2 are expressed in the microvasculature and ducts of human pancreas but are not enriched in beta cells

Expression of SARS-CoV-2 entry factors in the pancreas of normal organ donors and individuals with COVID-19

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

Neuropilin-1 is a host factor for SARS-CoV-2 infection

A Crisp(r) new perspective on SARS-CoV-2 biology

SARS-CoV-2 infects human pancreatic beta cells and elicits beta cell impairment

SARS-CoV-2 infection induces beta cell transdifferentiation

SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas

ACKNOWLEDGMENTS JS is supported by the Japan IDDM network and AMED-A*STAR SICORP.